For erlotinib and observation , respectively , the median progression-free survival was @ and @ months ( hazard ratio -LSB- HR -RSB- , @ ; @ % CI , @ to @ ) , and the median overall survival was @ and @ months ( HR , @ ; @ % CI , @ to @ months ) , respectively .